Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025
Rhea-AI Summary
Immuneering (Nasdaq: IMRX) announced a conference call and webcast scheduled for September 29, 2025, at 8:30 am ET to discuss recently released overall survival and safety data from their Phase 2a clinical trial. The trial evaluated atebimetinib + mGnP in 34 first-line pancreatic cancer patients with 9 months median follow-up.
The data will also be featured in a poster presentation at the PanCAN Scientific Summit 2025 on September 28. Interested parties can access the conference call via webcast or by dialing (800) 715-9871 (U.S.) or (646) 307-1963 (international) with conference ID 9502940.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, IMRX declined 16.46%, reflecting a significant negative market reaction. Argus tracked a trough of -10.1% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $66M from the company's valuation, bringing the market cap to $333M at that time.
Data tracked by StockTitan Argus on the day of publication.
NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it will host a conference call and live webcast at 8:30 am ET on September 29, 2025, to discuss recently announced updated overall survival and safety data in first-line pancreatic cancer patients treated with atebimetinib + mGnP (N=34) with 9 months median follow up.
“These exciting results were first announced in our press release on September 24, 2025, will be highlighted in a poster presentation at the Pancreatic Cancer Action Network (PanCAN) Scientific Summit 2025 on Sunday, and will be discussed during our conference call on Monday. We are committed to ensuring the community has multiple opportunities to engage with and understand these important results,” said Ben Zeskind, Ph.D., CEO of Immuneering.
Individuals interested in listening to the live conference call may do so through this webcast link or by dialing (800) 715-9871 in the U.S. or (646) 307-1963 for other locations and reference conference ID 9502940. A webcast replay will be available from the “Investors” section of the Company’s website here. The Immuneering September 2025 corporate presentation can be found here and the September 24, 2025 press release announcing updated overall survival and safety data in first-line pancreatic cancer patients can be found here.
About Immuneering
Immuneering is a clinical-stage oncology company focused on keeping cancer patients alive. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors. Immuneering’s lead product candidate, atebimetinib, is an oral, once-daily Deep Cyclic Inhibitor of MEK designed to improve durability and tolerability, and expand indications to include MAPK pathway-driven tumors such as most pancreatic cancers. Atebimetinib is currently in a Phase 2a trial in patients with advanced solid tumors including pancreatic cancer. The Company’s development pipeline also includes early-stage programs. For more information, please visit www.immuneering.com.
Media Contact:
Carson Creehan
817-412-1096
carson.creehan@padillaco.com
Investor Contact:
Laurence Watts
619-916-7620
laurence@newstreetir.com
FAQ
When is Immuneering's conference call to discuss pancreatic cancer trial results?
What clinical trial data will IMRX discuss in the September 29 conference call?
How can investors access Immuneering's September 29 conference call?
Where will Immuneering present their pancreatic cancer trial data before the conference call?
